Sino Biopharmaceutical (HK:1177) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Sino Biopharmaceutical has presented positive phase III study results for Culmerciclib in combination with Fulvestrant, showing significant improvement in progression-free survival and remission rates in HR+/HER2- advanced breast cancer patients. The promising data, which highlighted a 9.16-month median PFS extension and a 64% reduction in disease progression risk, was shared at the 2024 CSCO. The new drug application for this combination therapy has been submitted, indicating potential advancements in breast cancer treatment options.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
